Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

G1 Therapeutics Q1 2024 GAAP EPS $(0.20), Inline, Sales $14.476M Miss $15.259M Estimate

Author: Benzinga Newsdesk | May 01, 2024 06:31am
G1 Therapeutics (NASDAQ:GTHX) reported quarterly losses of $(0.20) per share which met the analyst consensus estimate. This is a 62.26 percent increase over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $14.476 million which missed the analyst consensus estimate of $15.259 million by 5.13 percent. This is a 11.82 percent increase over sales of $12.946 million the same period last year.

Posted In: GTHX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist